Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY.

Cancer Med. 2014 Dec;3(6):1579-94. doi: 10.1002/cam4.317. Epub 2014 Aug 13.

PMID:
25124282
[PubMed - in process]
Free PMC Article
2.

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.

Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.

Clin Cancer Res. 2005 Feb 15;11(4):1563-71.

PMID:
15746061
[PubMed - indexed for MEDLINE]
Free Article
3.

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B.

Carcinogenesis. 2013 Apr;34(4):739-49. doi: 10.1093/carcin/bgs393. Epub 2012 Dec 28.

PMID:
23275151
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.

Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16.

PMID:
24838527
[PubMed - in process]
5.

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y.

J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. doi: 10.1124/jpet.113.210146. Epub 2014 Mar 20.

PMID:
24650937
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.

Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, Poupon MF.

Clin Cancer Res. 2000 May;6(5):2075-86.

PMID:
10815935
[PubMed - indexed for MEDLINE]
Free Article
7.

Combination of arsenic trioxide and chemotherapy in small cell lung cancer.

Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC.

Lung Cancer. 2013 Nov;82(2):222-30. doi: 10.1016/j.lungcan.2013.08.022. Epub 2013 Sep 3.

PMID:
24041618
[PubMed - indexed for MEDLINE]
8.

IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.

Ferté C, Loriot Y, Clémenson C, Commo F, Gombos A, Bibault JE, Fumagalli I, Hamama S, Auger N, Lahon B, Chargari C, Calderaro J, Soria JC, Deutsch E.

Mol Cancer Ther. 2013 Jul;12(7):1213-22. doi: 10.1158/1535-7163.MCT-12-1067. Epub 2013 May 2.

PMID:
23640142
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The neurotoxin 1-methyl-4-phenylpyridinium: a selective cytostatic agent in small-cell lung cancer cell lines with neuroendocrine properties.

Marini AM, Fridman R, Kanemoto T, Martin GR, Guo Y, Passaniti A.

J Natl Cancer Inst. 1992 Oct 21;84(20):1582-7.

PMID:
1328660
[PubMed - indexed for MEDLINE]
10.

Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.

Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA.

Clin Cancer Res. 2013 Nov 15;19(22):6322-8. doi: 10.1158/1078-0432.CCR-13-1975. Epub 2013 Sep 27.

PMID:
24077350
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.

Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC.

Lung Cancer. 2013 May;80(2):216-22. doi: 10.1016/j.lungcan.2013.01.014. Epub 2013 Feb 12.

PMID:
23410825
[PubMed - indexed for MEDLINE]
12.

Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.

Jain N, Lam YM, Pym J, Campling BG.

Cancer. 1996 May 1;77(9):1797-808.

PMID:
8646677
[PubMed - indexed for MEDLINE]
13.

Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines.

Kubo S, Matsutani M, Nakagawa K, Ogura T, Esumi H, Saijo N.

J Cancer Res Clin Oncol. 1992;118(4):244-8.

PMID:
1315778
[PubMed - indexed for MEDLINE]
14.

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.

Cancer Res. 2007 Feb 1;67(3):1176-83.

PMID:
17283153
[PubMed - indexed for MEDLINE]
Free Article
15.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.

PMID:
14709739
[PubMed - indexed for MEDLINE]
Free Article
16.

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.

Cancer Res. 2003 Oct 1;63(19):6272-81.

PMID:
14559814
[PubMed - indexed for MEDLINE]
Free Article
17.

Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.

Hsu HW, de Necochea-Campion R, Williams V, Duerksen-Hughes PJ, Simental AA Jr, Ferris RL, Chen CS, Mirshahidi S.

Oral Oncol. 2014 Jul;50(7):662-9. doi: 10.1016/j.oraloncology.2014.03.006. Epub 2014 Apr 13.

PMID:
24735547
[PubMed - indexed for MEDLINE]
18.

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ.

Clin Cancer Res. 2007 May 1;13(9):2728-37.

PMID:
17473206
[PubMed - indexed for MEDLINE]
Free Article
19.

Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2.

Hillgenberg M, Schlehofer JR, von Knebel Doeberitz M, Klein-Bauernschmitt P.

Eur J Cancer. 1999 Jan;35(1):106-10.

PMID:
10211097
[PubMed - indexed for MEDLINE]
20.

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.

Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX.

Cell Cycle. 2011 Dec 1;10(23):4074-82. doi: 10.4161/cc.10.23.18170. Epub 2011 Dec 1.

PMID:
22101337
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk